MedTrace Logo

DP303c in Patients With HER2-positive Advanced Breast Cancer

NCT05901935 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2023-06-13

No results posted yet for this study

Summary

This is a study of DP303c in patients with HER2-positive advanced breast cancer.

Conditions

  • HER2-positive Advanced Breast Cancer

Interventions

DRUG

DP303c

DP303c injection, 3.0 mg/kg, Q3W.

DRUG

Trastuzumab

IV, 6 mg/kg, D1, Q3W

DRUG

Vinorelbine Tartrate

IV, 25 mg/m\^2，D1、D8，Q3W

DRUG

Capecitabine tablets

PO 1000 mg/m\^2, bid, D1-D14, Q3W

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2026-01-31
Completion
2028-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05901935 on ClinicalTrials.gov